FY2026 EPS Estimates for Viking Therapeutics, Inc. (NASDAQ:VKTX) Decreased by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) – Investment analysts at Leerink Partnrs lowered their FY2026 earnings per share estimates for shares of Viking Therapeutics in a note issued to investors on Tuesday, March 26th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will earn ($2.31) per share for the year, down from their previous forecast of ($2.30). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.10) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ FY2027 earnings at ($3.40) EPS and FY2028 earnings at ($1.21) EPS.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.25). During the same period in the prior year, the company posted ($0.26) EPS.

VKTX has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Viking Therapeutics in a research report on Tuesday, March 26th. Truist Financial raised their price objective on Viking Therapeutics from $32.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Oppenheimer raised their price objective on Viking Therapeutics from $116.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of Viking Therapeutics in a research report on Friday, March 15th. Finally, BTIG Research raised their price objective on Viking Therapeutics from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

Get Our Latest Stock Report on VKTX

Viking Therapeutics Price Performance

Shares of VKTX stock opened at $82.00 on Friday. Viking Therapeutics has a 1-year low of $8.28 and a 1-year high of $99.41. The stock’s 50-day moving average is $51.39 and its 200 day moving average is $27.24. The company has a market cap of $8.24 billion, a P/E ratio of -89.13 and a beta of 1.06.

Insider Transactions at Viking Therapeutics

In other news, CEO Brian Lian sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $23.95, for a total value of $838,250.00. Following the completion of the transaction, the chief executive officer now directly owns 2,264,882 shares in the company, valued at $54,243,923.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Greg Zante sold 15,000 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the completion of the transaction, the chief financial officer now directly owns 180,730 shares in the company, valued at $3,235,067. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian Lian sold 35,000 shares of Viking Therapeutics stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $23.95, for a total value of $838,250.00. Following the transaction, the chief executive officer now owns 2,264,882 shares of the company’s stock, valued at $54,243,923.90. The disclosure for this sale can be found here. Insiders sold a total of 374,079 shares of company stock worth $9,729,653 over the last three months. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VKTX. Swiss National Bank raised its position in Viking Therapeutics by 7.2% during the first quarter. Swiss National Bank now owns 166,500 shares of the biotechnology company’s stock valued at $500,000 after acquiring an additional 11,200 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Viking Therapeutics by 20.5% in the first quarter. JPMorgan Chase & Co. now owns 32,893 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,606 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Viking Therapeutics by 26.3% in the first quarter. Bank of New York Mellon Corp now owns 325,748 shares of the biotechnology company’s stock worth $977,000 after acquiring an additional 67,835 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Viking Therapeutics by 0.5% in the first quarter. BlackRock Inc. now owns 5,147,461 shares of the biotechnology company’s stock worth $15,442,000 after acquiring an additional 27,971 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Viking Therapeutics by 29.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,375,485 shares of the biotechnology company’s stock worth $4,126,000 after acquiring an additional 312,377 shares during the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

About Viking Therapeutics

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Read More

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.